A
Anja Williams
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 10
Citations - 74
Anja Williams is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 2 publications receiving 51 citations.
Papers
More filters
Journal ArticleDOI
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khurum Khan,Mihaela Rata,David Cunningham,Dow-Mu Koh,Nina Tunariu,Jens C. Hahne,George Vlachogiannis,Somaieh Hedayat,Silvia Marchetti,Andrea Lampis,Mahnaz Darvish Damavandi,Hazel Lote,Isma Rana,Anja Williams,Suzanne A. Eccles,Elisa Fontana,David J. Collins,Zakaria Eltahir,Sheela Rao,David Watkins,Naureen Starling,Jan Thomas,Eleftheria Kalaitzaki,Nicos Fotiadis,Ruwaida Begum,Maria Antonietta Bali,Massimo Rugge,Eleanor Temple,Matteo Fassan,Ian Chau,Chiara Braconi,Nicola Valeri +31 more
TL;DR: Combining DCE-MRI and ctDNA predicts duration of anti-angiogenic response to regorafenib and may improve patient management with potential health/economic implications.
Journal ArticleDOI
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
Thomas Walle,Sunanjay Bajaj,Joscha A. Kraske,T. Rösner,Christiane S Cussigh,Katharina A. Kälber,L. J. Müller,S.B. Strobel,Jana Burghaus,Stefan M. Kallenberger,Christoph Stein-Thöringer,Maximilian Jenzer,Antonia Schubert,Steffen Kahle,Anja Williams,Birgit Hoyler,Lin Zielske,Renate Skatula,Stefanie Sawall,Mathias F. Leber,Russell Kunes,Johannes Krisam,Carlo Fremd,Andreas Schneeweiss,Jürgen Krauss,Leonidas Apostolidis,Anne Berger,Georg Martin Haag,Stefanie Zschäbitz,Niels Halama,Christoph Springfeld,Jessica C. Hassel,Dirk Jäger,Omar Abdelrahim,Elena Busch,Patrick Derigs,Katharina Dischinger,Fouad Mitri,Kerstin Schmidt,Irfan A. Bhatti,Barbara Grün,Nicolas Hohmann,Lena Woydack,Xin-Wen Zhang,Dyke Ferber,Andreas Mock,Tillmann Pompecki,Timo Schank,Guy Ungerechts +48 more
TL;DR: In this paper , adverse events and serum cytokines in patients with 23 different tumors undergoing or not undergoing COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220).
Journal ArticleDOI
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.
Vasiliki Michalarea,Elisa Fontana,Alvaro Henrique Ingles Garces,Anja Williams,Elizabeth C Smyth,Simona Picchia,Sheela Rao,Ian Chau,David Cunningham,Maria Antonietta Bali +9 more
TL;DR: 6 cases of patients with gastrointestinal cancers who were treated with anti- PD1 and anti-PD-L1 (programmed cell death ligand-1) antibodies, and experience pseudoprogression are presented.
Journal ArticleDOI
Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
Martine Piccart,Audrey Hennequin,Manuel Ruiz Borrego,Santiago Escrivá-de-Romaní,Anja Williams,Begona Jimenez Rodriguez,Gianluca Del Conte,Sacha J Howell,Michela Palleschi,Matteo Simonelli,François Duhoux,D. Tosi,B. Doger De Speville Uribe,Yolanda Jerez Gilarranz,Pierfrancesco Tassone,Giuseppe Curigliano,Simon Waters,Philippe Aftimos,Hans Wildiers,Simona Scartoni,B. Piza Vallespir,Ram C. Shankaraiah,Krzysztof J. Grzegorzewski,Nassir Habboubi +23 more
TL;DR: Men1611 (Men) is an oral PI3K inhibitor active on the p110α mutant and wild type, β and γ isoforms, while sparing the δ as discussed by the authors .
Journal ArticleDOI
Ctni-49. early signal of activity from a phase 2 study of st101, a first-in-class peptide antagonist of ccaat/enhancer-binding protein β (c/ebpβ), in recurrent glioblastoma (gbm)
Fabio M. Iwamoto,Vinai Gondi,Nicholas Butowski,Gerald S. Falchook,Anja Williams,K. Peters,Jeff Evans,Nehal Lakhani,Meredith Ann McKean,Stefan Symeonides,Benjamin M. Ellingson,J. Rotolo,Gina M. Capiaux,Erol Wiegert,Rob Michel,Stephen Kaesshaefer,Alice S. Bexon +16 more
TL;DR: In this article , a cell-penetrating peptide antagonist of C/EBPβ, called ST101, was used to prevent selective tumor cell death in multiple human cancer cell lines, including GBM.